Anti-CD20 versus Dimethyl Fumarate as First-Line Treatment for Pediatric Multiple Sclerosis: A Retrospective Cohort Study

Abstract

Background

Consensus on the first-line treatment of pediatric-onset multiple sclerosis (POMS) remains unresolved. Recently, dimethyl fumarate (DMF) and anti-CD20 therapies have been among the favorable options for pediatric multiple sclerosis (MS).

Objective

This study aimed to determine the effectiveness and safety of DMF versus anti-CD20 therapies for POMS.

Methods

We conducted a retrospective cohort study from July 2012 to July 2022 in the Isfahan MS clinic. MS cases under the age of 18 years old who received DMF or anti-CD20 agents as first-line treatment and were followed for at least 12 months were included.

Results

About 124 POMS cases were screened, of which 39 met the inclusion criteria. About 23 patients received DMF, while 16 patients received anti-CD20 (rituximab or ocrelizumab). The median (interquartile range, IQR) annualized relapse rate (ARR) decreased significantly (both with p < 0.0001) from 2.63 (0.68) to 0.0 (1.0) in the DMF group and from 2.89 (1.39) to 0.0 (1.0) in the anti-CD20 group. The median (IQR) expanded disability status score insignificantly changed from 1.0 (1.0) to 1.0 (0.5) in the DMF group, while it changed from 1.25 (1.0) to 1.0 (0.5) in the anti-CD20 group. After 12 months of follow-up, 12/16 in the anti-CD20 group and 17/23 in the DMF group were relapse-free. None of the treatment outcomes were different between the two treatment cohorts. Our study also assessed adverse events (AEs).

Conclusion

While subject to replication in future clinical trials, both DMF and anti-CD20 therapies had a significant effect on reducing ARR and disease activity with an acceptable safety profile, but in our study, there were no differences in their efficacy.

Keywords

pediatric-onset multiple sclerosis - anti-CD20 - dimethyl fumarate - rituximab - ocrelizumab - disease-modifying treatment

• References

• 1 Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol 2019; 26 (01) 27-40
• 2 Yan K, Balijepalli C, Desai K, Gullapalli L, Druyts E. Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis. Mult Scler Relat Disord 2020; 44: 102260
• 3 Brola W, Steinborn B. Pediatric multiple sclerosis - current status of epidemiology, diagnosis and treatment. Neurol Neurochir Pol 2020; 54 (06) 508-517
• 4 Deiva K. Pediatric onset multiple sclerosis. Rev Neurol (Paris) 2020; 176 (1-2): 30-36
• 5 Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol 2018; 18 (01) 27
• 6 Krysko KM, Graves J, Rensel M. et al.; US Network of Pediatric MS Centers. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology 2018; 91 (19) e1778-e1787
• 7 Sharmin S, Roos I, Malpas CB. et al.; Writing Group, Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries. Lancet Child Adolesc Health 2024; 8 (05) 348-357
• 8 Etemadifar M, Nouri H, Sedaghat N. et al. Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review. Mult Scler Relat Disord 2024; 91: 105849
• 9 Montes Diaz G, Hupperts R, Fraussen J, Somers V. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmun Rev 2018; 17 (12) 1240-1250
• 10 Vermersch P, Scaramozza M, Levin S. et al. Effect of dimethyl fumarate vs interferon β-1a in patients with pediatric-onset multiple sclerosis: The CONNECT randomized clinical trial. JAMA Netw Open 2022; 5 (09) e2230439
• 11 Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS). Pediatr Neurol 2018; 83: 19-24
• 12 Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M. et al. Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis. Front Neurol 2021; 11: 606418
• 13 Krysko KM, Graves JS, Rensel M. et al.; US Network of Pediatric MS Centers. Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol 2020; 88 (01) 42-55
• 14 Chitnis T, Tenembaum S, Banwell B. et al.; International Pediatric Multiple Sclerosis Study Group. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012; 18 (01) 116-127
• 15 Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP. Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol 2024; 271 (01) 105-115
• 16 Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore) 2024; 103 (08) e37297
• 17 Etemadifar M, Kaveyee H, Ebne-Ali-Heydari Y. et al. Dimethyl fumarate for pediatric-onset multiple sclerosis: A systematic review. Pediatr Neurol 2025; 167: 52-59
• 18 Malani Shukla N, Casper TC, Ness J. et al.; U.S. Network of Pediatric Multiple Sclerosis Centers. Demographic features and clinical course of patients with pediatric-onset multiple sclerosis on newer disease-modifying treatments. Pediatr Neurol 2023; 145: 125-131
• 19 Breu M, Sandesjö F, Milos RI. et al. Rituximab treatment in pediatric-onset multiple sclerosis. Eur J Neurol 2024; 31 (05) e16228